Study shows that Probi probiotics may delay the onset of gluten intolerance in children

74f53ea4-6a0a-4f3a-aac1-1ec8215749d2articleimage.jpg

11 Sep 2017 --- A clinical trial evaluating the effect of probiotics from Probi in children genetically predisposed for gluten intolerance has shown that these probiotics have a suppressing effect on celiac autoimmunity and may delay the onset of the disease. Celiac disease affects up to 3 percent of the population, and currently, the introduction of a lifelong gluten-free diet is the only available treatment.

The randomized, double-blind, placebo controlled intervention study was performed by Dr. Daniel Agardh and his research team at Lund University with the objective of evaluating the effect of Probi’s probiotic strains Lactobacillus plantarum Heal 9 and Lactobacillus paracasei 8700:2 on Celiac Disease (CD) autoimmunity. Seventy-eight asymptomatic children (3-7 years old) with an increased risk for developing CD were randomly allocated to a daily consumption of either the probiotic product or a placebo for a total period of 6 months while on a gluten-containing diet. The 78 children were identified as a subpopulation in a multinational and multiyear autoimmunity study with thousands of children.

The study results show that the levels of the disease-related antibodies were significantly reduced in the probiotic group and significantly increased in the placebo group during the course of the study. In addition, several significant differences were observed between the groups on a cellular level indicating that the probiotic may counteract CD-associated ongoing immunological and inflammatory response.

“To our knowledge, this is the first time a probiotic study has been performed on this specific population and the results show immune-supporting properties of these probiotics as well as a potential preventive effect on the development of CD,” says Daniel Agardh.

“This is an excellent example of a well-working collaboration between academia and the industry” says Peter Nählstedt, CEO of Probi AB. “We see a growing interest in children’s probiotics and these results enable Probi to build a product platform for children.”

“The probiotic was administered in a sachet, and the subjects were instructed to sprinkle the powder on their food or dissolve it in water. Probi has recently launched a new fast melting powder formulation which would be a suitable format for a commercial product,” Nählstedt tells NutritionInsight

“This was a study in a population that has, to our knowledge, not been studied before. We are very excited about the good results and based on the evaluation of the data we will now build our product platform for children. For companies that are interested in marketing a product with the strains, Probi is able to formulate a fast melting powder or other desired product format,” Nählstedt adds.

Probi’s proprietary probiotic strains Lactobacillus plantarum Heal 9 and Lactobacillus paracasei 8700:2 are patent protected, of human origin and are commercially available. The results of the study were presented at the International Celiac Disease Symposium in New Delhi, India, on 10 September.

By Lucy Gunn

Related Articles

Nutrition & Health News

BioGaia probiotic found to reduce bone loss in older women

20 Nov 2017 --- Supplementation of the BioGaia probiotic strain Lactobacillus reuteri ATCC PTA 6475 decreased bone loss compared to placebo in 90 older women. This is according to the results of a randomized, double-blind, placebo-controlled study at the University of Gothenburg.

Nutrition & Health News

Gut bacteria sensitive to salt, linked to MS and hypertension: study

20 Nov 2017 --- Common salt reduces the number of certain lactic acid bacteria in the gut of mice and humans. This is according to a study published in the journal Nature by Berlin's Max Delbrück Center and Charité, which further notes an impact on immune cells that are partly responsible for autoimmune diseases like multiple sclerosis (MS) and hypertension. Probiotics were also found to ameliorate the symptoms of disease in mice.

Nutrition & Health News

Weight management – Keeping the kilos off (Part 3): Trends, innovation and strong opinions

17 Oct 2017 --- Weight management is a hot topic in the nutrition industry, and NutritionInsight has solicited the views of medical professionals and industry insiders on the next steps to take. Today, in the final part of a special report, we share the trends in the industry, some new R&D and expert opinions in the space in general.

Nutrition & Health News

Evolva to work with Northumbria University for studies on health benefits of resveratrol

17 Nov 2017 --- Evolva is entering a collaboration with Northumbria University’s Brain, Performance and Nutrition Research Centre in the UK for a series of studies on Veri-te resveratrol. The collaboration will include human intervention studies that will assess the inter-relationships between obesity, gut health (through microbiota populations), systemic inflammation, cognitive function, cerebral blood flow and peripheral blood flow and how all of these factors can be modulated by resveratrol dietary supplementation.

Nutrition & Health News

Weight management – Keeping the kilos off (Part 2): Challenges and delivery methods

15 Nov 2017 --- Weight management is a hot topic in the nutrition industry, and NutritionInsight has been asking for the views of medical professionals and industry insiders on the next steps to take. Today in the second part of a special report, we look at the challenges currently being presented to the industry and delivery methods being used for weight management products.

More Articles
URL : http://www.nutritioninsight.com:80/news/study-shows-that-probi-probiotics-may-delay-the-onset-of-gluten-intolerance-in-children.html